HEMISPHERX BIOPHARMA INC		
Form 8-K		
October 10, 2018		

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 9, 2018

HEMISPHERX BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware0 - 2707252-0845822(state or other jurisdiction of incorporation)(Commission (I.R.S. Employer File Number) (Identification No.)

860 N. Orange Avenue, Suite B, Orlando, FL (Address of principal executive offices)	32801 (Zip Code)
Registrant's telephone number, including area cod	de: (215) 988-0080
(Former name or former address, if changed since	e last report)
Check the appropriate box below if the Form 8-K the registrant under any of the following provision	filing is intended to simultaneously satisfy the filing obligation of ns (see General Instruction A.2. below):
[]Written communications pursuant to Rule 425	under the Securities Act (17 CFR 230.425)
[]Soliciting material pursuant to Rule 14a-12 un	der the Exchange Act (17 CFR 240.14a-12)
[]Pre-commencement communications pursuant	to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]Pre-commencement communications pursuant	to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
	an emerging growth company as defined in as defined in Rule 405 of ter) or Rule 12b-2 of the Securities Exchange Act of 1934
Emerging growth company []	
	ek mark if the registrant has elected not to use the extended transition ancial accounting standards provided pursuant to Section 13(a) of the

Item 1.01 Entry into a Material Definitive Agreement.

On October 9, 2018, Hemispherx Biopharma, Inc. (the "Company") executed a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in combination with checkpoint inhibitors (CPIs). The Phase IIa clinical trial will evaluate the immune-mediated effects of cytokine modulation in combination with CPIs in patients with primary resistance to CPI therapy. The protocol will seek to evaluate the combination of Ampligen and CPIs in patients with advanced urothelial carcinoma, renal cell carcinoma and melanoma. Ampligen is the Company's investigational immune-enhancing TLR3 agonist that has demonstrated a robust anti-cancer effect in preclinical models when combined with CPIs.

On October 10, 2018, the Company issued a press release regarding the agreement described above under Item 1.01 of this Current Report on Form 8-K. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

99.1 Press Release dated October 10, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMISPHERX BIOPHARMA, INC.

October 10, 2018 By:/s/ Adam Pascale Adam Pascale, CFO